All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Looking Beyond PSA Is Key to Understanding Nuances of Prostate Cancer Treatment

March 25th 2024

Robert Dreicer, MD, discusses the complex landscape of prostate cancer treatment, highlighting key points from his presentation at the 2024 NY GU.

Liposomal Annamycin Plus Cytarabine Generates Responses in AML

March 25th 2024

Liposomal annamycin plus cytarabine elicited responses in patients with acute myeloid leukemia, according to interim data from the phase 1b/2 MB-106 trial.

Momelotinib Efficacy Propels the Future Development of JAK Inhibitors in Myelofibrosis

March 25th 2024

Joseph G. Jurcic, MD, highlights findings from the phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials in myelofibrosis.

FDA Issues CRLs for Odronextamab in R/R Follicular Lymphoma and R/R DLBCL

March 25th 2024

The FDA issued complete response letters to the BLA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma.

Amer Zeidan, MBBS, MHS, Appointed Inaugural Chief of the Division of Hematologic Malignancies

March 25th 2024

Amer Zeidan, MBBS, MHS, has been appointed inaugural chief of the Division of Hematologic Malignancies at Yale Cancer Center.

Is It Time to Address the Fiscal Reality of the Cancer Care Model and Consider Alternatives?

March 25th 2024

Two items in the medical world should send chills down the spines of those considering the possible financial future of oncology care in the United States.

Taplin Tackles Equitable Treatment in Prostate Cancer

March 24th 2024

Mary-Ellen Taplin, MD, discusses ways to mitigate health care disparities in the treatment of patients with prostate cancer.

Post-Surgery Atezolizumab Fails to Provide Benefit in Combination With Chemotherapy for TNBC

March 23rd 2024

Adjuvant atezolizumab did not provide a clinical benefit when added to chemotherapy in patients with triple-negative breast cancer.

Phase 2 IMscin002 Study Shows Patients With NSCLC Prefer Subcutaneous Atezolizumab

March 22nd 2024

Patients with non–small cell lung cancer treated on the IMscin002 trial preferred subcutaneous atezolizumab vs the intravenous formulation.

Brexu-Cel Displays Superior Responses vs Pirtobrutinib in Relapsed/Refractory MCL Matching-Adjusted Indirect Comparison

March 22nd 2024

A matching-adjusted indirect comparison shows that brexu-cel is superior to pirtobrutinib regarding response and survival in relapsed/refractory MCL.

FDA Grants Full Approval to Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer

March 22nd 2024

The FDA has granted regular approval to mirvetuximab soravtansine-gynx for select patients with pretreated FRα-positive, platinum-resistant ovarian cancer.

Next-Generation JAK Inhibitors Signal the Future of Myelofibrosis Treatment Advances

March 22nd 2024

Joseph G. Jurcic, MD, discusses the benefits and limitations of several JAK inhibitors for patients with myelofibrosis.

Sylvester Appoints Prominent Oncologist-Researcher to Lead Transplantation and Cellular Therapy

March 22nd 2024

Damian Green, MD, will join Sylvester Comprehensive Cancer Center this spring to lead its transplantation and cellular therapy services.

Enzalutamide Receives Positive EU CHMP Opinion for High-Risk Biochemically Recurrent nmHSPC

March 22nd 2024

The EMA’s CHMP has recommended the approval of enzalutamide with or without androgen deprivation therapy in biochemically recurrent nmHSPC.

FDA Grants Fast Track Status to PT886 for Metastatic Claudin 18.2+ Pancreatic Adenocarcinoma

March 22nd 2024

PT886 has been granted fast track designation for use as a potential therapeutic option in patients with metastatic claudin 18.2–positive pancreatic adenocarcinoma.

Innovation Is the Answer to Making Progress Against Cancer

March 22nd 2024

Shanta Dhar, PhD, FRSC, discusses the significance of being named a fellow of the National Academy of Inventors for her research in prostate cancer.

Ribociclib Plus Nonsteroidal Aromatase Inhibitor Extends iDFS in HR+/HER2– Early-Stage Breast Cancer

March 22nd 2024

Ribociclib plus a nonsteroidal aromatase inhibitor bested nonsteroidal aromatase inhibitor therapy alone in terms of iDFS in early-stage breast cancer.

Avutometinib Plus Defactinib Shows High Response Rates in Heavily Treated LGSOC

March 21st 2024

Avutometinib plus defactinib led to tumor regression in most heavily pretreated patients with recurrent low-grade serous ovarian cancer.

FDA Green Lights Fluorouracil Safety Label Update Regarding Use in Patients With DPD Deficiency

March 21st 2024

The FDA has approved safety label changes for fluorouracil products to include information regarding the agent’s use in patients with DPD.

EZH2 Expression and TP53 Mutation Results in Inferior Outcomes in MCL

March 21st 2024

TP53 mutation and EZH2 expression negatively affect outcomes in mantle cell lymphoma, with a synergistic negative effect.